Navigation Links
Mylan's Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
Date:10/20/2011

BASKING RIDGE, N.J., Oct. 20, 2011 /PRNewswire/ -- Dey Pharma L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today confirmed that the U.S. Patent and Trademark Office (PTO) has issued Reexamination Certificates for two patents related to Perforomist® (Formoterol Fumarate) Inhalation Solution 20 mcg/2mL vial thereby confirming the validity of these patents. Sepracor, now known as Sunovion Pharmaceuticals, requested the PTO to re-examine these patents, which now has been completed.

Mylan Chairman and CEO Robert J. Coury commented: "We are pleased that the successful re-examination of these patents is complete as this only further strengthens our confidence in the intellectual property protecting our Perforomist product as well as our combination product currently in development. We are very excited about continuing to build on our brand division, Dey, which is and will continue to be an important growth driver for Mylan."

In addition to the two re-examined and granted patents, Dey owns five other relevant patents, giving it a total of seven U.S. patents which it believes are infringed by Sunovion's Brovana® product. In addition, Dey believes that Teva's Formotorol Fumarate product, which is the subject of an Abbreviated New Drug Application (ANDA) pending before the FDA, infringes several of Dey's U.S. patents. Mylan intends to vigorously defend its intellectual property in the pending patent litigations against Sunovion and Teva. The terms of the patents protecting Perforomist extend into 2021.  

About Dey Pharma

Dey Pharma, L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions and psychiatric disorders. The company puts patients first and facilitates efficient, cost-effective partnerships with customers. For more information, please visit www.dey.com.

About Mylan

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.

Forward Looking Statements

This press release includes statements that constitute "forward-looking statements", including with regard to pending litigation, products in development and expectations for Dey's future.  These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties inherent in legal proceedings; other legal or regulatory challenges; the impacts of competition; changes in economic and financial conditions of the company's business; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
2. Amylin Pharmaceuticals Reports Third Quarter Financial Results
3. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
4. USC School of Pharmacy to Double Presence in Safety-net Clinics
5. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
6. Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
7. ADVENTRX Pharmaceuticals to Present at the 10th Annual BIOInvestor Forum Conference on October 26
8. Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD
9. SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development
10. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
11. NASCSA Receives $200,000 Grant from Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase of ... and an increase of 1.2% on an adjusted pro forma, ... quarter were $0.52 reported, a decrease of 47.5% from the ... over the prior year period , The Company increases ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... 2016 , ... Hydra Skin Sciences, a top-rated skincare company based ... new anti-aging skin care product that integrates Snow Algae Powder and six ... seventy-five thousand units worldwide within the first two months of release. , “We set ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Dave Newberry, ... Pediatric Interim Care Center (PICC) annual fundraiser luncheon on Friday, May 20. “We ... helps the smallest victims of drug abuse,” said Newberry. , PICC is a local ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK Products, ... telemedicine stethoscope software that enables the stethoscope stream to go over the video ... with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves two software elements on ...
(Date:5/2/2016)... ... May 02, 2016 , ... ProElectric Cartoon is a package ... Pick and choose from a variety of electric styles including zap, sizzles, and more. ... customize shadow, dof blur, three dimensional rotation, and much more. ProElectric Cartoon’s simplistic style ...
(Date:5/2/2016)... ... ... Pets bring laughter, joy and love into people’s homes without asking for ... which falls on the first full week of May. These seven days, May 1 ... recognize responsible pet ownership. Pet owners can live out these values by following action ...
Breaking Medicine News(10 mins):